Skip to content

Study · Not a test of the peptide alone · 1992

4 results

Effect of immunisation against vasoactive intestinal polypeptide on gastric corpus tone and motility in the ferret.

Grundy D, Gharib-Naseri MK, Hutson D

Gut1 Nov 1992Cited by 4 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Other

    In ferrets immunised with a vasoactive intestinal polypeptide conjugate, plasma binding activity for the peptide increased versus unimmunised controls.

    In plain wordsIn ferrets, immunisation against VIP raised the blood's ability to bind VIP compared with unimmunised animals.

    Outcome
    IncreasePlasma VIP binding activity
    Study

    ferretn: not reported in source

    Immunisation against VIP (VIP-thyroglobulin conjugate)
    Comparator
    Unimmunised control animals
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    which resulted in a significant increase in plasma vasoactive intestinal polypeptide binding activity compared with unimmunised control animals.
    1 context sentence
    Summary · context
    The role of vasoactive intestinal polypeptide in the control of gastric corpus tone and motility was investigated using auto-antibodies to neutralise endogenous vasoactive intestinal polypeptide.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In ferrets immunised against vasoactive intestinal polypeptide, spontaneous gastric corpus motility after surgery was 15 times higher than in controls.

    In plain wordsIn ferrets, neutralising the body's own VIP was linked to much more spontaneous stomach movement than in controls.

    Outcome
    IncreaseSpontaneous gastric corpus motility
    Study

    ferretn: not reported in source

    Immunisation against VIP (VIP-thyroglobulin conjugate)
    Comparator
    Unimmunised control animals
    Outcome group
    Gastrointestinal motility · Gastrointestinal

    Measurements

    Spontaneous motility ratio
    15 times
    immunised vs control

    Source sentences

    Summary
    In acute experiments the level of spontaneous motility in the period immediately after completion of the surgical preparation was 15 times higher in immunised v control animals (p < 0.02).
    1 context sentence
    Summary · context
    The role of vasoactive intestinal polypeptide in the control of gastric corpus tone and motility was investigated using auto-antibodies to neutralise endogenous vasoactive intestinal polypeptide.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In ferrets immunised against vasoactive intestinal polypeptide, the gastric corpus showed no deficit in accommodating fluid.

    In plain wordsIn ferrets, neutralising the body's own VIP did not stop the stomach from accommodating fluid.

    Outcome
    No significant changeGastric corpus accommodation of fluid
    Study

    ferretn: not reported in source

    Immunisation against VIP (VIP-thyroglobulin conjugate)
    Comparator
    Unimmunised control animals
    Outcome group
    Gastrointestinal motility · Gastrointestinal

    Source sentences

    Summary
    Surprisingly, however, there was no deficit in the ability of the corpus to accommodate fluid.
    1 context sentence
    Summary · context
    The role of vasoactive intestinal polypeptide in the control of gastric corpus tone and motility was investigated using auto-antibodies to neutralise endogenous vasoactive intestinal polypeptide.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In ferrets immunised against vasoactive intestinal polypeptide, peak pressure at the end of a 20 ml ramp distension did not differ from controls.

    In plain wordsIn ferrets, neutralising the body's own VIP did not change peak stomach pressure compared with controls.

    Outcome
    No significant changePeak pressure at end of 20 ml ramp distension
    Study

    ferretn: not reported in source

    Immunisation against VIP (VIP-thyroglobulin conjugate)
    Comparator
    Unimmunised control animals
    Outcome group
    Gastrointestinal motility · Gastrointestinal

    Measurements

    Peak pressure
    5.7 cm H2O
    immunised
    Peak pressure
    4.8 cm H2O
    controls

    Source sentences

    Summary
    Peak pressure at the end of a 20 ml ramp distension was not different in immunised animals (5.7 (0.6) cm H2O) compared with controls (4.8 (0.3) cm H2O).
    1 context sentence
    Summary · context
    The role of vasoactive intestinal polypeptide in the control of gastric corpus tone and motility was investigated using auto-antibodies to neutralise endogenous vasoactive intestinal polypeptide.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.